Abaloparatide, Human PTHrP Peptide

Catalog#	Product Name	Availability	Size	Price	Qty
THP-0148	Abaloparatide, Human PTHrP Peptide	April 02, 2023	1mg	$998
Add to Cart Online Order Request a Bulk Order

Specification Drug Information Related Products

Cat#:	THP-0148
Product Name:	Abaloparatide, Human PTHrP Peptide
Description:	The product is an analog of PTHrP (parathyroid hormone-related protein), a synthetic peptide that is related to hPTHrP and has demonstrated in testing the potential to widen the anabolic window for bone therapeutics, stimulating bone formation with a limited effect on bone resorption and mineral mobilization. This could enable improved convenience over currently available anabolic therapies, resulting in greater compliance and, ultimately, greater benefit.
Sequences:	AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA
Species:	Human
Molecular Weight:	3961.0 Da
Source:	synthetic peptide
Purity:	>99.5% by SDS-Page and HPLC analysis
Cas No:	247062-33-5
Formula:	C174H300N56O49
Endotoxin Level:	<0.001 EU per 1 μg of the peptide by the LAL method
Biological Activity:	2000 ug/1mL
Storage:	Lyophilized peptide should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted peptide solution can be stored at 2-8 °C for 1 week. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Drug Name:	Abaloparatide
Applications:	Investigated for use/treatment in postmenopausal osteoporosis to reduce vertebral and/or non-vertebral fractures.
Examples of Clinical Use:	Postmenopausal osteoporosis
Pharmacodynamics:	The product, a proprietary analog of human parathyroid hormone-related protein (hPTHrP), is currently undergoing clinical trials by the company for the treatment of osteoporosis in postmenopausal women. PTHrP is a critical peptide for promoting new bone formation, with a distinct role from parathyroid hormone, or PTH, which primarily regulates calcium homeostasis and bone resorption. Clinical studies show increased bone mineral density (BMD) and levels of bone formation markers in a dose-response relationship.
Mechanism of action:	In target cells, abaloparatide acts as an agonist on PTH type 1 receptor (PTH1R) and activates both G protein–mediated cAMP signaling and β-arrestin-mediated ERK-1/2 signaling pathways with similar potency [A19105]. Abaloparatide binds to RG conformation of PTH1R with greater selectivity that results in more transient cell signalling responses.
Affected organisms:	Humans and other mammals
Targets:	Target 1. Parathyroid hormone/parathyroid hormone-related peptide receptor